Emactuzumab

Emactuzumab (RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) [1][2].

Product Specifications

CAS Number

[1448221-67-7]

Product Name Alternative

RG 7155; RO 5509554

UNSPSC

12352203

Target

C-Fms

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/emactuzumab.html

Purity

97.60

Solubility

10 mM in DMSO

Smiles

[Emactuzumab]

Molecular Weight

(144.41 kDa)

References & Citations

[1]Philippe A Cassier, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015 Aug;16 (8) :949-56.|[2]Carola H Ries, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25 (6) :846-59.